Tenofovir (Viread): News
 Tenofovir Linked With Risk of Kidney Damage (February 21, 2012)
In Positively Aware, from Test Positive Aware Network
- Tenofovir Label Extended to Pediatric Indication (January/February 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
- Viread: New Formulation and Pediatric Dosing Update (January 19, 2012)
From U.S. Food and Drug Administration
- Scientists "Tinker" With HIV Drug Chemistry Hoping to Reduce Costs (May 13, 2011)
In Kaiser Daily Global Health Policy Report, from Henry J. Kaiser Family Foundation
- Expanded Indication for Viread, to Include the Treatment of Patients 12 to Less Than 18 Years of Age (March 24, 2010)
From U.S. Food and Drug Administration
- FDA Approves Gilead's Antiretroviral Viread for Use as Hepatitis B Treatment (August 13, 2008)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Gilead Sciences May Lose Patent for Viread (January 25, 2008)
Looser patent laws could mean generic version of Tenofovir to come.
In Housing Works AIDS Issues Update, from Housing Works
- U.S. Patent Agency to Review Gilead's Claim on Tenofovir (July 20, 2007)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Gilead Lowers Its No-Profit Drug Prices for Truvada, Viread (August 30, 2005)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Viread (Tenofovir Disoproxil Fumarate) Labeling Revision (May 13, 2005)
Among the revisions is updated information regarding drug resistance and long-term effects on bone mineral density.
From U.S. Food and Drug Administration
- Warning on Two Specific 3-Drug Regimens: Viread + Videx + Either Sustiva or Viramune (November 23, 2004)
A brief comment on the recently issued warning that both regimens frequently fail.
In AIDS Treatment News, from AIDS Treatment News
- Two New Fixed-Dose Combinations Approved (August 2, 2004)
From U.S. Food and Drug Administration
- Food and Drug Administration to Expedite Decision on Emtricitabine/Tenofovir Pill (May 18, 2004)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Drug Development News: Fixed-Dose Combinations (May/June 2004)
The Food and Drug Administration's fast-track approval process for fixed-dose combinations is about to bear fruit.
In GMHC Treatment Issues, from Gay Men's Health Crisis
- Gilead Sciences First-Quarter Profits Driven by Increase in Sales of Antiretroviral Viread (April 26, 2004)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Atazanavir (Reyataz): New Recommendations if Combined With Tenofovir (Viread) -- and Warning on Viagra, Cialis, and Levitra (March 26, 2004)
New warnings on drug-drug interactions are noted in the prescribing information for atazanavir.
In AIDS Treatment News, from AIDS Treatment News
- Revised Labeling for Viread (Tenofovir Disoproxil Fumarate) 300 mg Tablets (November 4, 2003)
From U.S. Food and Drug Administration
- Gilead Warns Against Use of Triple-NRTI Regimen 3TC, ddI, Tenofovir (October 14, 2003)
To read PDF, click here.
From U.S. Food and Drug Administration
- FDA Orders Gilead for Second Time to Stop Downplaying Risks, Inflating Benefits of Antiretroviral Drug Viread (August 8, 2003)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Atazanavir/Tenofovir Combo Should Be Boosted With Ritonavir (August 8, 2003)
From U.S. Food and Drug Administration
- U.S. Approves Emtriva; Gilead Hopes Viread/Emtriva Combo Will Compete With Combivir (July 3, 2003)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
|
Advertisement
|
Email
Glossary
